Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro

[1]  G. Evan,et al.  c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. , 1999, Genes & development.

[2]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[3]  F. Lemonnier,et al.  Modulation of  Thymic Selection by Expression of an Immediate-early Gene, Early Growth Response 1 (Egr-1) , 1998, The Journal of experimental medicine.

[4]  H. Gudmundsdottir,et al.  Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. , 1997, The Journal of clinical investigation.

[5]  G. Evan,et al.  Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. , 1997, Science.

[6]  N. Copeland,et al.  Mad3 and Mad4: novel Max‐interacting transcriptional repressors that suppress c‐myc dependent transformation and are expressed during neural and epidermal differentiation. , 1995, The EMBO journal.

[7]  F. Chan,et al.  A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. , 1995, Immunity.

[8]  G. Evan,et al.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.

[9]  J. Sprent,et al.  T-cell apoptosis detected in situ during positive and negative selection in the thymus , 1994, Nature.

[10]  K. Alitalo,et al.  c‐Myc induces cellular susceptibility to the cytotoxic action of TNF‐alpha. , 1994, The EMBO journal.

[11]  G. Evan,et al.  c‐Myc‐induced apoptosis in fibroblasts is inhibited by specific cytokines. , 1994, The EMBO journal.

[12]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[13]  J. Sprent,et al.  Turnover of Naive-and Memory-phenotype T Cells , 1994 .

[14]  B. Amati,et al.  Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. , 1994, Current opinion in genetics & development.

[15]  E. Cameron,et al.  Conditional expression and oncogenicity of c‐myc linked to a CD2 gene dominant control region , 2009, International journal of cancer.

[16]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[17]  A. Bradley,et al.  A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. , 1993, Genes & development.

[18]  Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. , 1993, Molecular and cellular biology.

[19]  P. Marrack,et al.  The Bacterial and Mouse Mammary Tumor Virus Superantigens; Two Different Families of Proteins with the Same Functions , 1993, Immunological reviews.

[20]  R. Brent,et al.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.

[21]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[22]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[23]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[24]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[25]  D. Kioussis,et al.  A self-reactive T cell population that is not subject to negative selection. , 1992, International immunology.

[26]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[27]  K. M. Abraham,et al.  Developmental regulation of lck gene expression in T lymphocytes , 1991, The Journal of experimental medicine.

[28]  J. Bishop,et al.  The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.

[29]  M. Groudine,et al.  Control of c-myc regulation in normal and neoplastic cells. , 1991, Advances in cancer research.

[30]  R. Perlmutter,et al.  Dissection of thymocyte signaling pathways by in vivo expression of pertussis toxin ADP‐ribosyltransferase. , 1990, The EMBO journal.

[31]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[32]  M. Egerton,et al.  The kinetics of immature murine thymocyte development in vivo. , 1990, International immunology.

[33]  H. Boehmer,et al.  Developmental biology of T cells in T cell-receptor transgenic mice. , 1990 .

[34]  H. Kishi,et al.  Deletion of autospecific T cells in T cell receptor (TCR) transgenic mice spares cells with normal TCR levels and low levels of CD8 molecules , 1989, The Journal of experimental medicine.

[35]  D. Kioussis,et al.  Complex lymphoid and epithelial thymic tumours in Thyl-myc transgenic mice , 1989, Nature.

[36]  Y. Uematsu,et al.  Thymic major histocompatibility complex antigens and the αβ T-cell receptor determine the CD4/CD8 phenotype of T cells , 1988, Nature.

[37]  A. Berns,et al.  T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous α- and β-genes , 1988, Nature.

[38]  H. Boehmer,et al.  Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes , 1988, Nature.

[39]  L. Cote,et al.  GABA and its relationship to putrescine metabolism in the rat brain and pancreas , 1987, Neurochemistry International.

[40]  Eric Wickstrom,et al.  A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1 , 1987, Nature.

[41]  M. Cole.  The myc oncogene: its role in transformation and differentiation. , 1986, Annual review of genetics.

[42]  U. Siebenlist,et al.  The regulation and expression of c-myc in normal and malignant cells. , 1986, Annual review of immunology.

[43]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[44]  R. Palmiter,et al.  Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs. , 1985, Proceedings of the National Academy of Sciences of the United States of America.